Nasdaq: rvnc

See all ideas.

Revance Therapeutics, Inc. About the company. The company's lead drug candidate is DAXXIFY DaxibotulinumtoxinA-lanm for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. Trading at Revenue is forecast to grow Trading at good value compared to peers and industry.

Nasdaq: rvnc

.

Neutral Sell Buy. No longer forecast to breakeven Mar What are Revance Therapeutics, Inc.

.

Key events shows relevant news articles on days with large price movements. Karyopharm Therapeutics Inc. KPTI Evolus Inc. EOLS 1.

Nasdaq: rvnc

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. ZacksTrade and Zacks.

Courteney arquette

Revance Announces U. Aug RVNC long rvnc - long consolidation and accumulation. Divergence also visible on Monthly timeframe. Volatile share price over the past 3 months. To do this, you need to open an account and follow a broker's procedures, then start trading. EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. The company's lead drug candidate is DAXXIFY DaxibotulinumtoxinA-lanm for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. Key stats. New minor risk - Share price stability Oct See more stats in Revance Therapeutics, Inc. Analyst rating. Future Growth.

.

Market closed Market closed. Break of ascending triangle probably to happen. Market closed Market closed. Second quarter earnings: EPS and revenues miss analyst expectations Aug Market capitalization. New minor risk - Share price stability Oct See all ideas. How to buy Revance Therapeutics, Inc. See Fair Value and valuation analysis. You can trade Revance Therapeutics, Inc. But the RR looks pretty good to me. See all brokers. Health Technology. Keep reading Keep reading.